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located on the proximal arm (underlying bruising is
caused by recent trauma to the arm and is not a result of
the patient’s hemorrhagic bullous dermatosis).INTRODUCTION
Hemorrhagic bullous dermatosis is a rare, gener-
alized skin reaction with unknown pathogenesis,
described in association with heparin therapy.
Heparin is known to cause injection site reactions
and ecchymosis but rarely causes global cutaneous
reactions, making hemorrhagic bullous dermatosis
an unusual clinical entity. The condition occurs
within 5 to 21 days of the initiation of therapy at
locations distant to the site of subcutaneous heparin
injection. Characteristic lesions are painless, hemor-
rhagic papules on a background of uninvolved skin.
The histologic findings are usually nonspecific but
can help rule out thrombosis, vasculitis, or marked
inflammatory changes. Skin lesions usually resolve
after discontinuation of heparin. We present a case of
hemorrhagic bullous dermatosis in an 82-year-old
woman recently started on warfarin therapy and
briefly review skin effects of anticoagulation.Fig 2. Single hemorrhagic papule on the lateral fingertip.CASE REPORT
An 82-year-old woman with a medical history of
congestive heart failure, myelodysplastic syndrome,
thrombocytopenia, and discoid lupus erythematosus
was started on warfarin therapy for new-onset atrial
flutter. Ten days after initiation of treatment, she
presented with a sudden outbreak of painless,
nonpruritic, black papules on her extremities
(Figs 1 and 2). Given the concern for warfarin-
related skin necrosis, she was started on vitamin K
and switched to a daily subcutaneous injection of
enoxaparin as an alternative anticoagulation
treatment. Subsequently, she had epistaxis, which
required nasal packing. She was admitted to the
hospital 7 days after starting enoxaparin, because ofthe Dermatology Department, the Oregon Health and
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gusoa@ohsu.edu.her worsening skin condition, which now involved
her mucous membranes.
Physical examination found several 2- to 3-mm
discrete black, purpuric papules, some with over-
laying hemorrhagic crust, distributed on her face,
arms, dorsal and palmar hands, and feet. SimilarJAAD Case Reports 2016;2:156-8.
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Fig 3. Results of a punch biopsy showed epidermal hyperplasia (A) and dilated vessels and
epithelial necrosis with fibrin deposition (B). (Hematoxylin-eosin stain; original magnifications:
A, 340; B, 3100.)
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showed a chronic anemia related to her myelodys-
plastic syndrome (hemoglobin, 9.1 g/dL). She had
acute on chronic thrombocytopenia, with a platelet
count of 33 K/mm3. Results of a heparin-platelet
factor 4 test were negative. Results of comprehensive
metabolic panel, antiedouble-strandedDNA, and C3
and C4 tests were all within normal limits.
Coagulation studies were notable for mildly elevated
international normalized ratio and partial thrombo-
plastin time of 1.29 and 54.7 seconds, respectively. A
4-mm biopsy from the left big toe found focal
parakeratosis overlying a hyperplastic epidermis,
within which were dilated vessels, surrounded by a
collarette of epithelium and epithelial necrosis with
fibrin deposition, without evidence of vasculitis,
capillary thrombosis, or significant inflammatory
infiltrate (Fig 3). Discontinuation of anticoagulant
therapy resulted in spontaneous regression of her
lesions.
DISCUSSION
Hemorrhagic bullous dermatosis is a blistering
eruption associated with heparin therapy. A charac-
teristic report of this entity came from Perrinaud et al1
in 2006. Interestingly, the pathogenesis of this
condition remains poorly understood.1 Both
unfractionated heparin and low-molecular-weight
heparin have been implicated, and to our
knowledge, as few as 14 cases have been reported
in the literature.1-7 This is an unusual case of
hemorrhagic bullous dermatosis associated with
warfarin monotherapy. In cases described with
heparin initiation, this entity typically appears within
5 to 21 days and presents as numerous asymptomatic
and tense, blood-filled bullae and papules on
uninflamed skin. These lesions involve areas distant
to the injection site. Laboratory studies are generally
within normal limits. Histopathology often shows
nonspecific intraepidermal or subcorneal vesiclesfilled with red blood cells without evidence of
vasculitis, capillary thrombosis, or significant inflam-
matory infiltrate. The condition resolves without
sequelae after heparin is discontinued or may
spontaneously resolve despite continued heparin
use. Heparin skin reactions are normally confined
to the site of injection, making the global distribution
of hemorrhagic bullous dermatosis particularly
unusual. Injection site reactions may be immune
mediated or noneimmune mediated and include
skin necrosis, hematomas, ecchymoses, erythema-
tous plaques, nodules, angioedema, dermatitis, and
urticaria.3,8 Heparin rarely causes generalized skin
reactions, although diffuse necrosis may signify the
cutaneous manifestation of heparin-induced throm-
bocytopenia, a serious paradoxical hypercoagulable
state.
Cutaneous toxicities associatedwithwarfarin, such
as dermatitis and urticaria, are rare. Themost dreaded
complication, skin necrosis, is seen in about 0.01% to
0.1% of patients.8 Like heparin-induced thrombocy-
topenia, warfarin-induced skin necrosis is a paradox-
ical hypercoagulable reaction, causing occlusive
thrombi in cutaneous and subcutaneous venules. It
occurs early on in treatment, usually within 3 to
10 days. The conditionmanifests suddenly as painful,
erythematous plaques with predilection for adipose-
rich areas such as the buttocks, hips, and breasts but
may occur on extremities and the penis.8 Plaques
transform into bullae, which blister and develop into
full-thickness skin necrosis. Affected patients often
have a history of receiving an initial large loadingdose
ofwarfarin.Ourpatient’s recent trial ofwarfarin raised
concern for skin necrosis. However, her history was
not consistent with skin necrosis, as she received a
prophylactic dose of warfarin, and her skin lesions
were painless.
Reports of hemorrhagic bullous dermatosis in
patients receiving 2 or even 3 blood thinning agents,
has led to speculation that the dermatosis may be a
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ture does not fully support overanticoagulation as
the primary pathogenesis, and there are numerous
case reports of hemorrhagic bullous dermatosis
presenting in patients on heparin monotherapy
with coagulation studies and platelet levels
within normal limits. It is unclear what role our
patient’s chronic thrombocytopenia or myelodys-
plastic syndrome played in the development of her
skin condition. To our knowledge, thrombocyto-
penia has not been a reported laboratory abnormal-
ity among previous case reports of hemorrhagic
bullous dermatosis. Our patient’s cutaneous reaction
to warfarin in the setting of chronic thrombocyto-
penia may be an idiosyncratic reaction or represent a
previously unrecognized medication reaction in
thrombocytopenic patients, although it is difficult
to draw any conclusions from a single case report.
Furthermore, the worsening of the patient’s
condition after discontinuation of warfarin and
initiation of enoxaparin may be because of
combined anticoagulant effects or represent a
secondary and more severe reaction to enoxaparin.REFERENCES
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